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ABSTRACT
Introduction Glucose variability is associated with 
mortality and macrovascular diabetes complications. 
The mechanisms through which glucose variability 
mediates tissue damage are not well understood, although 
cellular oxidative stress is likely involved. As heat shock 
proteins (HSPs) play a role in the pathogenesis of type 2 
diabetes (T2D) complications and are rapidly responsive, 
we hypothesized that HSP- related proteins (HSPRPs) 
would differ in diabetes and may respond to glucose 
normalization.
Research design and methods A prospective, 
parallel study in T2D (n=23) and controls (n=23) was 
undertaken. T2D subjects underwent insulin- induced blood 
glucose normalization from baseline 7.6±0.4 mmol/L 
(136.8±7.2 mg/dL) to 4.5±0.07 mmol/L (81±1.2 mg/
dL) for 1 hour. Control subjects were maintained at 
4.9±0.1 mmol/L (88.2±1.8 mg/dL). Slow Off- rate Modified 
Aptamer- scan plasma protein measurement determined a 
panel of HSPRPs.
Results At baseline, E3- ubiquitin- protein ligase (carboxyl- 
terminus of Hsc70 interacting protein (CHIP) or HSPABP2) 
was lower (p=0.03) and ubiquitin- conjugating enzyme 
E2G2 higher (p=0.003) in T2D versus controls. Following 
glucose normalization, DnaJ homolog subfamily B 
member 1 (DNAJB1 or HSP40) was reduced (p=0.02) in 
T2D, with HSP beta-1 (HSPB1) and HSP-70- 1A (HSP70- 
1A) (p=0.07 and p=0.09, respectively) also approaching 
significance relative to T2D baseline levels.
Conclusions Key HSPRPs involved in critical protein 
interactions, CHIP and UBE2G2, were altered in diabetes 
at baseline. DNAJB1 fell in response to euglycemia, 
suggesting that HSPs are reacting to basal stress that 
could be mitigated by tight glucose control with reduction 
of glucose variability.
INTRODUCTION
The chronic hyperglycemia of type 2 diabetes 
(T2D) results from a combination of 
progressive pancreatic islet β-cell failure and 
increased insulin resistance (IR)1 A progres-
sive increase in its prevalence means that T2D 
is now the fourth leading cause of mortality.2 
This has led to an increase in diabetes- related 
complications and, while their molecular 
mechanisms are increasingly understood, 
new molecular therapeutic targets are needed 
to prevent the microvascular and macrovas-
cular diabetes- related complications such as 
nephropathy, retinopathy, heart failure, and 
limb amputation.
Heat shock proteins (HSPs) are critical 
proteins classified by molecular weight3 that 
suppress protein aggregation, assist in folding 
and stability of nascent/damaged proteins, 
chaperone proteins into cellular compart-
ments and target irreversibly damaged 
proteins for degradation under physiolog-
ical and stressful conditions.4 HSPs bind and 
control the activity of critical enzymes for 
inflammation, apoptosis, metabolism and 
cell signaling, and genetic manipulation of 
Significance of this study
What is already known about this subject?
 ► Heat shock proteins (HSPs) are important in the 
pathogenesis of type 2 diabetes (T2D) and its com-
plications, and glucose variability is associated with 
mortality and macrovascular diabetes complications.
What are the new findings?
 ► Key HSPs, carboxyl- terminus of Hsc70 interacting 
protein and ubiquitin- conjugating enzyme E2G2 
(UBE2G2), proteins critical for optimal functioning 
of intracellular protein degradation pathways, were 
altered at baseline in the patients with diabetes.
 ► Higher levels of DNAJB1(HSP40) have been linked 
to insulin resistance; here, DNAJB1 levels fell sig-
nificantly with euglycemic normalization of blood 
glucose in the T2D subjects.
 ► On achieving euglycemia in T2D subjects, HSPB1, 
a chaperone protein involved in protection of the 
proteome from stress, and HSP70- 1A, a protein 
member of the HSP70 family also involved in pro-
tection of the proteome from stress by targeting and 
direction of misfolded proteins for either refolding or 
degradation, also approached significance relative 
to baseline levels.
 ► These data suggest an additional mechanism to 
account for the effect of glucose variability on 
diabetes- related complications.
How might these results change the focus of 
research or clinical practice?
 ► HSP levels are altered in response to basal stress 
in T2D, and their levels can be normalized by good 
glucose control and reduction of glucose variability.
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certain HSPs, or modulation of their expression, has 
revealed their role in the pathogenesis of several chronic 
diseases including diabetes and its complications.5–9 
They have also been indicated to play a role in ß-cell 
dysfunction and IR.10 Hyperglycemia leads to downreg-
ulation of protective HSPs.11 HSPs appear to have a role 
in diabetes complications: elevated HSP27 has been asso-
ciated with diabetic neuropathy5 and diabetic nephrop-
athy,6 while diabetic retinopathy has been associated 
with HSP7012 13 that is inversely related to macrovascular 
complications.13 14 Consequently, HSPs have been consid-
ered as potential therapeutic targets.3
Improved management of T2D involves stricter 
glucose control, but the effect on HSP levels on achieving 
euglycemia from hyperglycemia has not previously been 
studied. In non- diabetic individuals during exercise, 
glucose has been shown to attenuate the circulating HSP 
response, indicating a relationship between HSP and 
glucose.15 Low glucose levels in the hypoglycemic range 
are associated with HSP70 inducible form HSP72 though 
it was unclear whether this is simply a marker of hypogly-
cemia or has a more functional role.16 Changes in HSP 
expression have been functionally related to hypergly-
cemia, and glucose variability has been associated with 
mortality and macrovascular diabetes complications, 
perhaps through increased tissue damage mediated 
by oxidative stress (OS), though the mechanisms are 
unclear.17 The HSP response is rapid and acute hyper-
glycemia is associated with downregulation of protec-
tive HSPs;11 therefore, we hypothesized that HSPs 
would differ in diabetes and may respond to glucose 
normalization.
RESEARCH DESIGN AND METHODS
Study design
T2D (n=23) and control (n=23) Caucasian subjects, 
aged between 40 and 70 years, were enrolled in a case- 
controlled study.
All participants provided written informed consent and 
were identified as previously described.18
In the T2D cohort, the duration of diabetes was <10 
years and all T2D subjects had been on a stable dose of 
medication (metformin, statin and/or ACE inhibitor/
angiotensin receptor blocker) for the prior 3 months. For 
inclusion of patients with T2D, only metformin as antidi-
abetic therapy was allowed; other inclusion criteria were 
HbA1c<10% (86mmol/mol)], and that patients had no 
history of hypoglycemic unawareness or hypoglycemia 
within the prior 3- month period. In the control group, 
diabetes was excluded with an oral glucose tolerance test. 
All subjects had a body mass index (BMI) between 18 and 
49 kg/m2, normal renal and hepatic biochemical indices 
and no prior history of cancer, or any contraindication to 
insulin infusion to achieve hypoglycemia (ischemic heart 
disease, epilepsy, seizure history, drop attacks, history of 
adrenal insufficiency, and treated hypothyroidism).
All participants had a medical history, clinical exam-
ination, routine blood tests, and an ECG performed 
(table 1). The ECG was normal in all subjects.
The hyperinsulinemic clamp was performed as 
reported;19 in brief, all patients underwent a 10- hour fast 
prior to the clamp. T2D: baseline glucose 7.6±0.4 mmol/L 
(136.8±7.2 mg/dL), reduced to 4.5±0.07 mmol/L 
(81±1.2 mg/dL) for 1 hour. Controls: 4.9±0.1 mmol/L 
(88.2±1.8 mg/dL). Hemacue blood glucose samples were 
collected every 5 min to monitor the glucose lowering 
progression and samples for proteomic analysis were 
collected at baseline and after 1 hour of euglycemia.19
Following the hyperinsulinemic clamp, participants 
were given lunch and the T2D cohort were provided 
their (morning) diabetes medications; patients later took 
their evening medication as prescribed.
Biochemical markers
Blood samples were separated immediately by centrifu-
gation at 2000 g for 15 min at 4°C, and the aliquots were 








Age (years) 64±8 60±10 <0.0001
Sex (M/F) 13/10 9/14 0.25
Weight (kg) 90.9±11.1 79.5±8.8 <0.0001
Height (cm) 167±14 169±5 0.64
BMI (kg/m2) 32±4 28±3 <0.0001
Systolic BP (mm Hg) 132±8 122±8 0.001
Diastolic BP (mm Hg) 81±7 75±6 0.003
Duration of diabetes 
(years)
4.5±2.2 N/A
Fasting plasma glucose 
(mmol/L)
7.6±0.4 4.9±0.1 <0.0001
HbA1c (mmol/mol) 51.2±11.4 37.2±2.2 <0.0001











CRP (mg/L) 3.0±2.7 5.1±10.3 0.33
Insulin (IU/mL) 13.7±7.6 21.6±44.2 0.41
HOMA- IR 4.8±3.8 4.8±9.6 0.99
Data are presented as mean±SD.
BMI, body mass index; BP, blood pressure; CRP, C reactive 
protein; HDL- cholesterol, high- density lipoprotein cholesterol; 
HOMA- IR, Homeostatic Model Assessment- Insulin Resistance; 
LDL- cholesterol, low- density lipoprotein cholesterol.
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stored at –80°C, within 30 min of blood collection, until 
batch analysis. Fasting plasma glucose, total cholesterol, 
triglycerides, and high- density lipoprotein cholesterol 
levels were measured enzymatically using a Beckman AU 
5800 analyser (Beckman- Coulter, High Wycombe, UK).
SOMA-scan assay
Slow Off- rate Modified Aptamer (SOMA)- scan plasma 
protein measurement19 was used to determine a panel 
of heat shock and related proteins, namely HSP-90- 
alpha/beta (HSP90alpha- A1/HSP90alpha- B1), HSP-70 
(HSP70- 1A), Heat shock cognate 71 kDa protein (HSP70-
8), HSP- beta-1 (HSPB1), 60 kDa HSP, mitochondrial 
(HSPD1), hsp90 co- chaperone Cdc37 (CDC37), dnaJ 
homolog subfamily B member-1 (DNAJB1), peptidyl- 
prolyl cis- trans isomerase D (PPID), stress- induced- 
phosphoprotein-1 (STIP1), E3 ubiquitin- protein 
ligase (carboxyl- terminus of Hsc70 interacting protein 
(CHIP) or HSPABP2), Ubiquitin- conjugating enzyme 
E2 G2 (UBE2G2) and HSP 90 dimer (HSP90a/b). The 
SOMAscan assay was performed on an in- house Tecan 
Freedom EVO liquid handling system (Tecan Group, 
Maennedorf, Switzerland) using buffers and SOMA-
mers from the SOMAscan HTS Assay 1.3K plasma kit 
(SomaLogic, Boulder, Colorado, USA) according to 
manufacturer’s instructions and as described previ-
ously.20 21 The assay was performed in 96- well plates 
containing up to 85 plasma samples, 3 quality control, 
and 5 calibrator plasma samples. Briefly, EDTA plasma 
samples were diluted into bins of 40%, 1%, and 0.05% 
and incubated with streptavidin- coated beads immobi-
lized with dilution- specific SOMAmers via a photocleav-
able linker and biotin. After washing, bound proteins 
were first biotinylated and then released from beads by 
photocleaving the SOMAmer- bead linker. The released 
SOMAmer- protein complex was treated with a polyan-
ionic competitor to disrupt unspecific interactions and 
recaptured on the second set of streptavidin- coated 
beads. Thorough washing was performed before 5’ Cy3 
fluorophore labeled SOMAmers were released under 
denaturing conditions, hybridized on microarray chips 
with SOMAmer- complementary sequences, and scanned 
using the SureScan G2565 Microarray Scanner (Agilent, 
Santa Clara, California, USA).
Data processing and analysis
Initial relative fluorescent units (RFUs) were obtained 
from microarray intensity images using the Agilent 
Feature Extraction Software (Agilent, Santa Clara, Cali-
fornia, USA). Raw RFUs were normalized and calibrated 
using the software pipeline provided by SomaLogic. 
This included (a) microarray hybridization normal-
ization based on spiked- in hybridization controls, (b) 
plate- specific intensity normalization, (c) median signal 
normalization, and (d) median calibrator scaling of 
single RFU intensities according to calibrator reference 
values. Samples with a high degree of hemolysis (Hapto-
globin log RFU <10) were excluded from the analysis.
Statistical analyses were performed on log2 RFU values 
using R V.3.5.2 (R Foundation for Statistical Computing, 
Vienna, Austria) including base R package. Data handling 
and differential protein expression were analyzed using 
the autonomics and limma22 packages. For differential 
protein analysis, we applied limma models containing 
contrasts between timepoints, as well as contrasts between 
healthy and patients with diabetes at single timepoints. 
In both models, blocking by patient ID was performed 
to account for random effects. Batch effect correction 
was performed by adding batch as a covariate to the 
model. Limma obtained p values were corrected using 
the Benjamini- Hochberg method.23
Statistical analysis
There are no studies detailing the changes in HSP 
response to hypoglycemia resulting from a hyperinsulin-
emic clamp intervention on which to base a power calcu-
lation. Sample size for pilot studies has been reviewed by 
Birkett and Day.24 They concluded that a minimum of 20 
degrees- of- freedom was required to estimate effect size 
and variability. Hence, we needed to analyze samples from 
a minimum of 20 patients per group. Data trends were 
visually evaluated for each parameter and non- parametric 
tests were applied on data that violated the assumptions 
of normality when tested using the Kolmogorov- Smirnov 
Test. Comparison between groups was performed at each 
timepoint using Student’s t- test. P<0.05 was considered 
statistically significant. Within- group comparisons are as 
follows: changes from baseline, and from hypoglycemia, 
to each subsequent timepoint were compared using 
Student’s t- test. The sample size was too small to adjust 
for baseline covariates. Statistical analysis was performed 
using Graphpad Prism (San Diego, California, USA).
Protein-protein interaction; STRING analysis
STRING 11.0 (Search Tool for the Retrieval of Interacting 
Genes) was used to visualize the known and predicted 
Protein- Protein Interactions for proteins identified by 
SOMAscan assay in plasma of T2D versus control subjects 
(https:// string- db. org/). Interactions between proteins 
are evidence- based and collated from databases, exper-
iments, neighborhood, gene fusion, co- occurrence, text 
mining, coexpression, and homology. Here, we deter-
mined the relationships between the HSPs presented in 
this study.
RESULTS
T2D subjects (n=23) were older than control subjects 
(n=23) (p<0.0001). T2D had higher BMI (p<0.0001) with 
duration of diabetes 4.5±2.2 years.
HSP and related protein changes are shown in table 2. 
Of the 13 proteins studied in this panel, CHIP was signifi-
cantly lower (p=0.03) and UBE2G2 higher (p=0.003) 
at baseline in T2D versus controls, while there was no 
difference between controls and T2D subjects at baseline 
for HSP90alpha- A1/HSP90alpha- B1, HSP70- 1A, HSC70, 
4 BMJ Open Diab Res Care 2021;9:e002057. doi:10.1136/bmjdrc-2020-002057
Pathophysiology/complications
HSPB1, HSPD1, CDC37, DNAJB1, PPID, STIP1, and HSP 
90a/b.
Following the hyperinsulinemic clamp, DNAJB1 was 
significantly reduced (p=0.02) in T2D with decreases in 
HSPB1 and HSP70- 1A (p=0.07 and p=0.09, respectively) 
also approaching significance relative to T2D baseline 
levels (figures 1 and 2). Since age and obesity are related 
to lower intracellular HSPs and higher circulating HSPs 
levels,25 we performed correlations of the HSPs with age 
and BMI. There was a negative correlation for HSP70- 1A 
(r=0.47, p=0.03) and HSPD1 (r=0.53, p=0.0093) with age 
in T2D and a positive correlation for HSPB1 (r=0.57, 
p=0.0049) with age in controls. There was a negative 
correlation of HSPD1 (r=0.54, p=0.007) and a positive 
correlation of UBE2G2 (r=0.42, p=0.044) with BMI in 
T2D only (figure 3).
As alterations in HSP responses have been documented 
in menopausal women,26 we subdivided our T2D and 
control cohorts according to gender. Of the 13 HSPs, the 
only gender difference was seen with HSP70- 1A that was 
higher in T2D women vs T2D men (p=0.012).
STRING analysis revealed that plasma CHIP showed 
the association and network with the other identified 
HSPs in the study, but that UBE2G2 was only linked 
to CHIP (figure 4), although there was no correlation 
between the two in plasma for either controls or T2D 
subjects (data not shown).
CONCLUSION
CHIP was significantly lower and UBE2G2 higher at 
baseline in the diabetes versus control patients. CHIP 
(HSPABP2) modulates the action of the chaperone 
proteins HSC70/HSP70 (HSP70- 1A),27 suggesting that 
the lower level may be associated with lower HSP activity, 
though the actual protein level measured did not differ.28 
In addition, CHIP, through E3 ubiquitin ligase activity, is 
a key factor in the cellular protein degradation pathway29 
and its decrease may impair protein degradation leading 
to toxic oligomers, increased reactive oxygen species 
(ROS and ultimately beta cell apoptosis.
UBE2G2 is a ubiquitin- conjugating enzyme modifying 
proteins with ubiquitin and necessary for misfolded 
protein degradation. UBE2G2 interacts with the U- box of 
C terminus of the HSP70 interacting protein CHIP and 
are closely linked.28
DNAJB1 belongs to the HSP40 family and higher levels 
are linked to IR.30 DNAJB1 decreased significantly in 
response to serum glucose normalization in T2D with 
decreases in HSP70- 1A and HSPB1 also approaching 
significance. It should be noted that the levels of DNAJB1 
were comparable at baseline between controls and T2D, 
and therefore its fall in response to induction of eugly-
cemia seen in T2D would seem discrepant but theo-
retically is due to a change in sensitivity of response in 
T2D. However, a fall in DNAJB1 would be in accord with 
a predicted decrease in HSP with the fall in glucose to 
normality; DNAJB1 acts through CHIP to modulate 
HSP70 to affect degradation of damaged protein and, 
therefore, lower levels, as seen here with the development 
of euglycemia, are beneficial. Hypothetically, modula-
tion of DNAJB1 in response to glucose may be one of 
the mechanisms underlying clinical glucose variability 
through improved glucose metabolism and hepatic IR 
inferred from animal experiments31 that may reflect on 
tissue damage effects reported for glucose variability17 
and represents a target for therapeutic intervention.
Table 2 Comparison of heat shock and related proteins between control (n=23) and type 2 diabetes (n=23) subjects at 
baseline and comparison of heat shock and related proteins between diabetes at baseline and following establishment of 









mean±SD (RFU) P value
HSP90alpha- A1 174±39.2 165±38.0 0.22 165±38.0 168±39.4 0.38
HSP90alpha- B1 17308±3046 17951±3127 0.24 17951±3127 18023±2975 0.47
HSP70- 1A 5686±1161 5300±1157 0.13 5300±1157 4983±1229 0.09
HSP70-8 1126±236 1043±192 0.82 1043±192 1045±141 0.18
HSPB1 1766±703 1592±604 0.19 1592±604 1344±552 0.07
HSPD1 3588±2260 3840±2805 0.37 3840±2805 3378±1399 0.24
CDC37 280±31.4 290±40.0 0.18 290±40.0 282±30.2 0.25
DNAJB1 404±111 396±93.3 0.39 396±93.3 343±77.0 0.02
PPID 545±297 660±355 0.12 660±355 552±311 0.14
STIP1 4656±1271 4467±944 0.28 4467±944 4518±818 0.42
CHIP 802±256 519±93.4 0.03 519±93.4 522±105 0.46
UBE2G2 3525±828 4331±1049 0.003 4331±1049 4365±1359 0.9
HSP 90a/b 4598±1031 4967±854 0.1 4967±854 4740±800 0.18
HSP, heat shock protein; HSPB1, heat shock protein beta-1; PPID, peptidyl- prolylcis- transisomerase D; RFU, relative fluorescent unit; STIP1, 
stress- induced- phosphoprotein-1; T2D, type 2 diabetes; UBE2G2, ubiquitin- conjugating enzyme E2G2.
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Glycemic variability is associated with diabetes compli-
cations possibly through increased tissue damage medi-
ated by OS.17 Nitric oxide (NO), a pleiotropic regulator 
of several biological processes and a potent endogenous 
vasodilator, is produced by three isoforms of the enzyme 
NO synthase (NOS), which includes endothelial NOS 
(eNOS), inducible NOS (iNOS), and neuronal NOS.32 
In diabetes, endothelial dysfunction occurs because 
of increased NO inactivation by ROS.33 Hyperglycemia 
downregulates eNOS in human coronary artery endothe-
lial cells, thus contributing to the inactivation of NO that 
leads to endothelial dysfunction in diabetes.34 By contrast, 
hyperglycemia induces iNOS production and contributes 
to hepatic IR in ob/ob mice.35 CHIP facilitates ubiquitina-
tion of iNOS and promotes its proteasomal degradation.36 
Moreover, CHIP regulates eNOS trafficking through the 
Golgi compartment by a co- chaperone- dependent mech-
anism which includes HSP70 and HSP90.37 Since hyper-
glycemia downregulates eNOS, we would expect higher 
CHIP in plasma in patients with T2D; however, our 
data demonstrated a lower basal level of CHIP in T2D, 
suggesting either hyperglycemia- induced inhibition 
of eNOS involving a mechanism independent to CHIP 
or that CHIP expression is downregulated as a conse-
quence of altered physiological changes in T2D. HSP70 
and HSP90 are also linked to inducible NO synthase and 
endothelial NO synthase expression,38 and CHIP targets 
NO synthase in concert with HSP70 while also modu-
lating the activity of several chaperone complexes which 
include HSC/HSP70 and HSP90 among others.36 39 
CHIP also acts as a co- chaperone for HSP70, promoting 
ubiquitin- mediated protein degradation.39 Therefore, 
both glucose variability and the expression of HSPs are 
associated with OS.
In previous reports, insulin upregulated eNOS expres-
sion in human coronary endothelial cells and the action 
of insulin was abolished by glucagon.34 Our data demon-
strated 1.7- fold increased basal glucagon levels (data not 
shown) in T2D; therefore, it is also possible that hyper-
glucagonemia is associated with a lower level of CHIP 
in T2D. Further studies that involve endocrine factors 
responsible for glucose variability and their relation to 
the expression of HSPs would be beneficial to eluci-
date the mechanism of altered HSPs levels and activity 
in T2D. Future research focusing on diacron- reactive 
oxygen metabolites test40 and/or a biological antioxidant 
potential test41 might allow an evaluation of the oxidant- 
antioxidant status before and after the clamp interven-
tion in human with T2D.
Figure 1 Comparison of HSPs HSP90alpha- A1, HSP90alpha- B1, HSP70- 1A, HSP70-8, HSPB1, 60 kDa heat shock protein, 
mitochondrial (HSPD1), CDC37, and DNAJB1 in plasma at BL and after iatrogenic induction of euglycemia (BM) in T2D 
subjects. Blood sampling for proteomics was performed at baseline (BL) in controls (white circles) and T2D (black squares) 
and again at euglycemia (BM) in T2D subjects. Proteomic (Somalogic) analysis of HSP- related proteins was undertaken for 
HSPs HSP90alpha- A1 (A), HSP90alpha- B1 (B), HSP70- 1A (C), HSP70-8 (D), HSPB1 (E), HSPD1 (F), CDC37 (G), and DNAJB1 
(H). Statistics: $p<0.05, T2D BL vs BM. BL, baseline; CDC37, hsp90 co- chaperone Cdc37; DNAJB1, dnaJ homolog subfamily 
B member-1; HSP, heat shock protein; HSP70- 1A, heat shock protein-70; HSP70-8; heat shock cognate 71 kDa protein; 
HSP90alpha- A1, heat shock protein-90- alpha; HSP90alpha- B1; heat shock protein-90- beta; HSPB1, heat shock protein- 
beta-1; HSPD1, 60 kDa heat shock protein, mitochondrial; RFU, relative fluorescent units; T2D, type 2 diabetes.
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HSP70- 1A is a protein member of the HSP70 family 
involved in protection of the proteome from stress. 
HSP70- 1A ensures quality control of protein folding 
by targeting and direction of misfolded proteins for 
either re- folding or degradation.42 HSP70- 1A interacts 
with CHIP and the HSP40 family proteins to promote 
ubiquitin- mediated protein degradation.27
The data reported here is in accord with other reports 
that HSP70 and 90 did not differ significantly from the 
controls though; conversely, HSP70 has been reported 
to be elevated in T2D though HSP90 did not differ.43 
The level of HSP70- 1A, a HSP70 family member, was 
lower in T2D than in controls, though not significantly 
so, in accord with those reporting lower HSP70 levels 
in diabetes,44 and with the return to euglycemia the 
levels decreased further. HSP90 and HSP70 expression 
levels have been linked with T2D;43 45 HSP70 levels have 
been reported to be lower in T2D, with a euglycemic 
clamp raising HSP70 expression while not influencing 
HSP90,45 suggesting that increased glucose levels may 
increase HSPs that are reversed when the glucose falls 
to normal. It has been noted that HSP70 can be glycated 
in a hyperglycemic environment that reduces its chap-
erone activity but it is unclear if that also affects plasma 
and tissue levels.46 Notably, circulating levels of HSP70 
have also been reported to be higher in people who are 
insulin resistant in comparison to the healthy subjects 
and normalize after duodenal–jejunal bypass.47
It has been previously noted that gender difference 
may alter HSP levels, as was particularly seen in post-
menopausal women,26 through the effect of estrogen via 
NO production on the HSP70 family. Here, HSP70- 1A, a 
HSP70 family member, was lower at baseline in T2D and 
is thought to predispose to chronic inflammatory disease, 
obesity and T2D;26 indeed the negative correlation of 
HSP70- 1A with BMI (here, higher in T2D subjects) shown 
here may in part account for this finding in patients with 
T2D. Whether glycemic variability may therefore have a 
Figure 2 Comparison of HSPs PPID, STIP1, CHIP, UBE2G2 and heat shock protein 90 dimer (HSP90a/b) in plasma at BL and 
after iatrogenic induction of euglycemia (BM) in T2D subjects. Blood sampling for proteomics was performed at baseline (BL) in 
controls (white circles) and T2D (black squares) and again at euglycemia (BM) in T2D subjects. Proteomic (Somalogic) analysis 
of HSP- related proteins was undertaken for HSPs PPID (A), STIP1 (B), CHIP (C), UBE2G2 (D), and HSP90a/b (E). Statistics: * 
p<0.05, BL, T2D vs control; **p<0.01, BL, T2D vs control. BL, baseline; CHIP, carboxyl- terminus of Hsc70 interacting protein; 
HSP, heat shock protein; PPID, peptidyl- prolyl cis- trans isomerase D; RFU, relative fluorescent units; STIP1, stress- induced- 
phosphoprotein 1; T2D, type 2 diabetes; UBE2G2, ubiquitin- conjugating enzyme E2G2.
7BMJ Open Diab Res Care 2021;9:e002057. doi:10.1136/bmjdrc-2020-002057
Pathophysiology/complications
greater impact on HSPs in postmenopausal women with 
diabetes requires further research, but it is recognized 
that women with diabetes have more serious complica-
tions than men.48 However, it should be noted that the 
subanalysis by gender in this study involved very few 
subjects and needs to be repeated on a much larger 
population to exclude false negative results.
The STRING analysis showed the close association and 
relationships between the differing HSPs and CHIP in 
this study, but only CHIP was related to UBE2G2 in the 
pathway, showing that the changes in CHIP may impact 
directly on UBE2G2, in accord with studies showing the 
close interaction between ubiquitin ligase CHIP and 
ubiquitin conjugating enzymes,49 though no correlation 
was seen here between CHIP and UBE2G2 in controls 
or T2D. The higher UBE2G2 in T2D at baseline would 
suggest that there was an increase in protein misfolding; 
however, baseline CHIP was lower, suggesting either that 
the close interaction between CHIP and the ubiquitin 
conjugating enzymes was disconnected or, more likely, 
that an alternative pathway was driving UBE2G2.
Only a few changes in HSPs were seen and this may 
be due to two possible scenarios. First, since it has been 
described that diabetic and obese subjects, as well as 
menopausal women have a poor heat shock response 
(low ability to increase HSP synthesis or release these 
proteins into the bloodstream), the reduced ability 
to produce a heat shock response may be reflected in 
the results presented here.50 Furthermore, it has been 
described that the duration of diabetes and the sum of 
comorbidities (obesity plus diabetes) show higher levels 
of extracellular HSPs (higher blood concentrations);26 51 
therefore, these subjects may not respond with new HSP 
release after a glycemic “challenge.” Second, the change 
in blood glucose in this study was within the clinically 
relevant range anticipated in normal diabetes regulation 
and therefore, at most, a modest “glycemic” challenge, 
or, indeed, could be considered as not a challenge at all 
but rather a return to an optimal homeostatic glycemic 
state.
A limitation of this study is the measurement of HSP 
proteins that may not reflect tissue level expression. In 
addition, the approaching significance noted in response 
to euglycemia for HSP70- 1A and HSPB1 in T2D relative 
to baseline may have actually reached significance with 
larger patient numbers.
These data have clinical importance as it may be seen 
that modest glucose fluctuation was associated with 
changes in HSPs and it may be that greater glucose 
excursions have greater impact on HSP levels. Therefore, 
changes in HSP level and function are clearly affected 
by glucose variability that, in turn, has been associated 
with mortality and macrovascular diabetes complications, 
perhaps through increased tissue damage mediated by 
OS; though the mechanisms are unclear, it may be medi-
ated via HSP responses. Optimal diabetes control has 
Figure 3 Correlation analyses of heat shock proteins. For age, there was a negative correlation with HSP70- 1A (A) and 
HSPD1 (C) in T2D (blue squares) and a positive correlation for HSPB1 (B) in controls (black squares). For BMI, there was a 
negative correlation with HSPD1 (D) and a positive correlation with UBE2G2 (E). BMI, body mass index; HSP, heat shock 
protein; HSPB1, HSP beta-1; RFU, relative fluorescent units; T2D, type 2 diabetes; UBE2G2, ubiquitin- conjugating enzyme 
E2G2.
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been well recognized to “result in fewer disease- related 
symptoms and a reduced risk of late complications,”52 but 
does not obviate the risk or their development entirely, 
and a degree of glucose variability is inherent in diabetes 
treatment.
In future studies, it would be valuable to monitor 
plasma levels of other stress markers, such as cortisol, 
to determine their correlation and temporal relation-
ship to the HSPs. It would also be interesting to deter-
mine whether manipulating the expression of HSPs via 
various means (genetic, pharmacological, diet, or phys-
ical activity) is feasible and if, thereby, modulation of 
IR and type 2 diabetes is possible. It would be valuable 
to investigate the HSP levels and responses following 
the use of pharmacological agents that may circumvent 
hypoglycemia while maintaining strict glycemic control, 
such as GLP-1 receptor agonists that are reported to have 
pleiotrophic effects on the unfolded protein response 
through a reduction in endoplasmic reticulum stress.53
In conclusion, HSP proteins involved in critical protein 
interactions were lower in diabetes, and DNAJB1 (HSP40) 
fell significantly with euglycemia, suggesting that HSPs 
are reacting to basal stress that can be improved in part by 
good glucose control and reduction of glucose variability.
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